Eli Lilly's Mounjaro becomes second-most sold drug in September, posts Rs 80 cr revenue: Report

Mounjaro is sold in two injectable dosage forms with the price ranging from Rs 14,000 to Rs 17,500 per month.

Eli Lilly's weight-loss drug Mounjaro (tirzepatide) became the second-most sold medicine in terms of value in India in September, in a sign of growing popularity of such drugs, a report by Business Standard said on October 8.

The US-based drugmaker registered a revenue of Rs 80 crore during the month, jumping 42 percent from its August revenue of Rs 56 crore, the paper said citing data from Pharmarack.

Augmentin, sold by GlaxoSmithKline, was the top selling drug in the country with a revenue of Rs 85 crore, BS said.

The massive jump in sales of the weight loss drug was due to a surge in demand and a shift towards higher dosage, the report said citing experts.

So far, Mounjaro has garnered a cumulative revenue of Rs 233 crore since its launch in March, the report said.

Mounjaro is sold in two injectable dosage forms with the price ranging from Rs 14,000 to Rs 17,500 per month.

Meanwhile, Eli Lilly announced on October 7 that it will invest $1 billion in the country in the next few years to boost its manufacturing and supply through local drugmakers in its efforts to increase its expansion.

The company currently does not operate its own manufacturing facility in the country, which hosts several firms that develop and manufacture complex drugs, vials, injectables for larger pharmaceuticals on a contract basis.

Lilly's investment plans in India come at a time when global drugmakers are rushing to bolster U.S. manufacturing capacity after the Trump administration imposed a 100% tariff on imported branded and patented drugs from October 1.

With agency inputs